ViaDerma, Inc.

Equities

VDRM

US92555K1016

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 17:41:21 31/05/2024 BST			5-day change	1st Jan Change
0.0067 ^USD	-0.74%		-2.90%	-36.79%

2023	ViaDerma, Inc. Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product	CI
2023	ViaDerma Announces Intent to Launch New Minoxidil Hair Regrowth Product	CI

ViaDerma, Inc. Appoints Dr. Andrew Berman as Medical Director of Advisory Board

November 13, 2014 at 04:26 pm

ViaDerma, Inc. announced the appointment of Dr. Andrew Berman as the Medical Director of the advisory board. Dr. Andrew Berman, M.D., MPH, is a Beverly Hills, California doctor affiliated with area hospitals including Cedars Sinai Medical Center and Midway-Olympia Hospital.

Latest news about ViaDerma, Inc.

ViaDerma, Inc. Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product	16/03/23	CI
ViaDerma Announces Intent to Launch New Minoxidil Hair Regrowth Product	08/03/23	CI
ViaDerma, Inc. Successfully Completes Quality Control Testing of Its New Vitastem Products	15/09/22	CI
ViaDerma, Inc. Set to Launch Two New and Improved Versions of Its Flagship Product, Vitastem and Vitastem Ultra	04/10/21	CI
ViaDerma, Inc. Provides Updates on Current Business Activities	24/06/21	CI
ViaDerma, Inc. Announces Expansion of Its Current Licensing Agreement	02/06/21	CI
ViaDerma, Inc. Nearing Initial Order from Large Hospital Network	13/05/21	CI
ViaDerma, Inc. Provides Revenue Guidance for the First Quarter of 2021	08/04/21	CI
ViaDerma, Inc. Completes a Licensing Agreement with a Group of Affiliate Wound Care Medical Practices Operating in Six States	21/01/21	CI
ViaDerma, Inc. Enters into A $250,000 Initial Sales Agreement with Vage Nigeria Ltd	24/04/18	CI
ViaDerma, Inc. Grants Approval to sell VitaStem(TM) its FDA Registered Topical Antibiotic on Amazon.com and Expands Testing into Major US Hospital Chains to Ramp Up Domestic Sales & Begins Production of New Products	21/11/17	CI
ViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx	19/10/17	CI
ViaDerma, Inc. Receives National Drug Code from the FDA for Prolayed	27/06/17	CI
Viaderma, Inc. Receives Positive Results on Phase I Testing in Canada with its Proprietary THC Delivery and Moves to Phase II Trials and Development of New Products with its MMJ Technologies	15/05/17	CI
Viaderma, Inc. Enters the Sexual Dysfunction Market & Files with the Food and Drug Administration for New OTC Drug to Conquer Premature Ejaculation for Men	05/04/17	CI
ViaDerma, Inc. Hires Ivan Klarich to Manage Quality Control Labeling, Marketing and Distribution of its Go to Market Product Line Launch	08/03/17	CI
ViaDerma, Inc. Signs Licensing and Distribution Agreement with Two Pharmaceuticals Companies for its FDA Registered Drug	11/01/17	CI
ViaDerma, Inc. Announces Preston Richards to Join Advisory Board	22/01/15	CI
ViaDerma, Inc. Announces TetraStem	09/12/14	CI
ViaDerma, Inc. Appoints Dr. Andrew Berman as Medical Director of Advisory Board	13/11/14	CI
ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA	30/10/14	CI
Décor Products International, Inc. will Change its Name to ViaDerma, Inc	06/05/14	CI

Chart ViaDerma, Inc.

Duration

Period

More charts

Company Profile

ViaDerma, Inc. is a specialty pharmaceutical company engaged in bringing new products to market and licensing its transdermal drug delivery technology solutions. The Companyâs lead product is a topical antibiotic, which is focused on being sold under the brand name Vitastem. In addition to licensing its proprietary transdermal technologies, its lead product, Vitastem, is available for treating multiple skin conditions and ailments. The Company also has products in development in fields, such as anti-aging skin care, pain management, hair-loss, and toenail fungus. The products are based on a delivery system technology that allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy. The Companyâs products are sold to local medical practitioners and patients in clinics primarily in the Los Angeles, California area. The Companyâs subsidiary is ViaDerma, II Inc.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIADERMA, INC.	-36.79%	8.33M
MODERNA, INC.	+42.76%	58.06B
IQVIA HOLDINGS INC.	-5.65%	40.53B
LONZA GROUP AG	+37.52%	38.99B
ICON PUBLIC LIMITED COMPANY	+14.38%	26.7B
CELLTRION, INC.	-12.56%	26.56B
ALNYLAM PHARMACEUTICALS, INC.	-21.68%	18.98B
BIO-TECHNE CORPORATION	-0.62%	12.17B
UNITED THERAPEUTICS CORPORATION	+23.57%	12B
MEDPACE HOLDINGS, INC.	+25.08%	11.92B

Other Biotechnology & Medical Research